Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...